These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: One year evaluation of immunogenicity conferred by a Chinese hamster ovary cell recombinant hepatitis B vaccine in a French Polynesian newborn immunization programme.
    Author: Spiegel A, Boutin JP, Cartel JL, Chanteau S, Cardines R, Saliou P, Roux JF.
    Journal: Trans R Soc Trop Med Hyg; 1991; 85(6):783-7. PubMed ID: 1801354.
    Abstract:
    In 1988, a hepatitis immunization programme, using a Chinese hamster ovary (CHO) cell recombinant vaccine, was implemented for newborn children in the Austral archipelago (French Polynesia). Three different schedules were used: (i) 4 vaccine doses at months (M) 0, M1, M2 and M12; (ii) 3 vaccine doses at M0, M1, M6; and (iii) 3 vaccine doses at M0, M1, M2. Results at the one year follow-up may be summarized as follows. Of 197 infants who received one or more doses of CHO-recombinant vaccine, (i) none was an HBsAg carrier; (ii) 89.5% had anti-HBs-antibody titres greater than 10 miu/ml; and (iii) 95.9% had seroconverted for at least one of the 2 antibodies studied (anti-HBs or anti-pre-S2). After 2 doses (M0, M1), anti-HBs seroconversion rate and geometric mean titre were, respectively, 82.6% and 98.47 miu/ml. After 3 doses, seroconversion rates and geometric mean titres were, respectively, 91.1% and 200.59 miu/ml using schedule M0, M1, M2, and 100% and 1253.4 miu/ml using the M0, M1, M6 schedule. None of the 7 vaccinated neonates born to HBsAg/HBeAg positive mothers was found to be an HBsAg carrier. These preliminary results indicate that, in field conditions, vaccination with a CHO-recombinant vaccine resulted in high immunogenicity.
    [Abstract] [Full Text] [Related] [New Search]